Stock comparison
IDEXX Laboratories
TransMedics Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
TMDX
TransMedics Group
Market cap
$2.18B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TMDX | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 51C | IDXX |
| Benjamin Graham | 72B | 55C | IDXX |
| Philip Fisher | 67B | 54C | IDXX |
| Peter Lynch | 63C | 87A | TMDX |
| Joel Greenblatt | 75B | 42D | IDXX |
| Charlie Munger | 79B | 48D | IDXX |
| Terry Smith | 76B | 41D | IDXX |
Side-by-side metrics
| Metric | IDXX | TMDX |
|---|---|---|
| Market cap | $42.11B | $2.18B |
| P/E (TTM) | 39.0x | 12.6x |
| EV/EBIT | 31.6x | 23.4x |
| ROIC (TTM) | 40.66% | 6.94% |
| Gross margin | 62.05% | 59.09% |
| Net margin | 24.63% | 27.04% |
| Revenue CAGR 5y | 7.56% | 111.5% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 1.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $2.18B+95%
- ROIC (TTM)40.66%vs 6.94%+83%
- Debt / Equity0.7xvs 1.7x+58%
TMDX leads on
- Revenue CAGR 5y111.5%vs 7.56%+93%
- P/E (TTM)12.6xvs 39.0x+68%
- EV/EBIT23.4xvs 31.6x+26%
- Net margin27.04%vs 24.63%+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.